Natco Pharma: The financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY…
Natco Pharma (NATCOPHARM) filed a disclosure titled "The financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27". The company is valued at about ₹14,357 crore.
What happened
Natco Pharma (NATCOPHARM) filed a disclosure with the exchanges on 13 November 2026 at 02:15 PM titled "The financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27".
From the filing: "Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27"
Company snapshot
Natco Pharma is a small-cap company in the Healthcare sector, with a market value of about ₹14,357 crore.
The stock last traded at ₹801.6, against a 52-week range of ₹773.6–₹1,216.8 (34.1% below the high).
Before this filing the shares had moved +1.1% over the month and −10.9% over three months. Average daily turnover over the last 20 sessions was about ₹37.35 crore.
Promoters held 49.42% at the end of Q1 FY27. Foreign institutions owned 16.99% and domestic institutions 5.62%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,329 | 480.7 | 26.84 |
| Q2 FY26 | 1,363 | 518.4 | 28.94 |
| Q3 FY26 | 647 | 151.5 | 8.46 |
| Q4 FY26 | 739 | 267.9 | 14.96 |
| Q1 FY27 | 735 | 206.5 | 11.53 |
What history shows
This is not the company's first results disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 20.6% on average the next trading day and was down 24.0% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.9% over five days; 58% of them rose the next day.
Market-wide, 11,743 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 29 May 2026 | Audited Financial Results For The Quarte And Year Ended 31St March,… | −20.6% | −24.0% |
| 29 May 2026 | Board Meeting Outcome for Audited Financial Results For The Quarter… | −20.6% | −24.0% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 13 November 2026: Board meeting — Financial Results/Dividend.
In the news
Recent coverage elsewhere (links open the original publisher):
- Khaitan & Co acts on NATCO Pharma ₹1,279 crore rights issue
- Natco Pharma Q2FY27 Results: Net profit falls 61% YoY to ₹203 crore
- Natco Pharma stock: Promoters acquire 2.21 million rights shares
- Natco Pharma declares interim dividend of ₹1.25 per share
- Natco Pharma stock awaits results and dividend decision Friday
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.